MetaVia's DA-1726: A Promising Solution for Liver Disease and Obesity Presented at ObesityWeek 2026

MetaVia Unveils DA-1726’s Potential in Treating Liver Disease and Weight Management



At ObesityWeek® 2026, held in Washington, D.C., MetaVia Inc. (Nasdaq: MTVA), a biotechnology company in the clinical development stage, presented groundbreaking preclinical data. The focus was on DA-1726, a dual-receptor agonist exhibiting significant efficacy in addressing liver-related diseases and aiding weight loss. This innovative compound operates by targeting GLP-1 (GLP1R) and glucagon (GCGR) receptors, making it a potentially game-changing treatment for conditions like Metabolic and Alcohol-Associated Liver Diseases (MetALD and ALD).

Insights from Preclinical Trials


The preclinical results suggest DA-1726 outperformed the existing weight loss treatment, retatrutide, in several important metrics. Notably, DA-1726 demonstrated a statistically significant increase in hepatic fibroblast growth factor 21 (FGF21) levels, crucial for lipid and carbohydrate metabolism regulation. The research indicated that DA-1726 not only enhanced FGF21 protein levels but also showed an increased expression of genes linked to energy expenditure and thermogenesis.

In a controlled study utilizing diet-induced obese (DIO) mice, DA-1726 injections yielded remarkable results. The data indicated that this dual agonist achieved greater glucose lowering than retatrutide, accompanied by notable weight loss without as much reliance on appetite suppression. For instance, plasma glucose levels plummeted by 43.0% for the lower dose of DA-1726 compared to reductions of 21.5% with retatrutide, proving the former’s superior efficacy.

Weight Loss and Appetite Regulation


The ability of DA-1726 to induce weight loss similar to retatrutide yet with lesser reduction in food intake marks a significant difference. Body weight reductions were noted at 34.2% and 41.7% for DA-1726 in comparison to 33.7% and 43.6% for retatrutide at various dosages. This contrasts impressively against food intake reductions; DA-1726's reductions were measured at 19.6% and 31.2%, while retatrutide showed 36.7% and 41.4%.

These findings underscore the possibility that DA-1726’s mechanisms of action could contribute to weight loss through increased energy expenditure linked to glucagon receptor pathways.

Future Prospects


Hyung Heon Kim, the President and CEO of MetaVia, expressed optimism surrounding DA-1726’s potential. He emphasized the importance of increased hepatic FGF21 levels and the meaningful weight loss achieved with less suppression of appetite. Kim stated, “These findings further support DA-1726's differentiated metabolic profile.”

MetaVia is gearing up for a Phase 2 study in 2027 aimed at exploring DA-1726's applications for MetALD and ALD. The study promises to further validate the positive outcomes observed in preclinical settings and potentially revolutionize treatment approaches for various cardiometabolic conditions.

Conclusion


The implications of DA-1726 could significantly impact the management of liver diseases and obesity, providing a new beacon of hope for patients struggling with these serious conditions. As MetaVia moves forward with their clinical investigations, the anticipation builds around DA-1726’s promise in the therapeutic landscape.

For those in the medical and research community, the developments surrounding DA-1726 are not to be overlooked, as they highlight a potential breakthrough in treating some of the most prevalent health issues of our time.

For further details, please visit MetaVia's website.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.